Christine Lindenboom
Next question.
Operator
Thank you. Our next question comes from the line of Paul Matteis of Stifel. Your line is open.
Paul Matteis
Hey. Thanks so much. I was really interested in your comments in the press release and in the prepared remarks on drug positioning related to the Inflation Reduction Act and kind of broader drug pricing risk. And to that point, you just filed a CTA for a once annual TTR knockdown drug. How do you think about positioning that and kind of balancing Stargardt versus this potentially just being a next-gen and TTR cardiomyopathy and also enabling you to maintain premium pricing beyond a decade in that space? Thanks so much.
Yvonne Greenstreet
Thank you for the question here. I think look, the inflation reduction is a significant shift in Medicare and how the Federal Government regulates our industry. We are supportive of the new Part D patient out-of-pocket caps, but we have considerable concerns about a couple of other aspects of the legislation. Clearly, the first is around concerns a small molecule medicines, face negotiated Medicare reimbursement rates only 9 years after approval compared to 13 years for monoclonal antibodies. I think very pertinent to us in the near-term is that while the exemptions in the Inflation Reduction Act from Medicare price negotiation for a drug that has a single orphan drug indication, they are now this incentive to pursuing the approval of drugs that in additional indications. Look, we are still digesting the legislation. But as you pointed out, in the meantime, besides the patisiran Phase 3 study in Stargardt disease, as we consider options for the best path forward. I would like to just kind of note three points really. One is that we remain excited actually by the opportunity for an RNAi-mediated TTR lowering method as a potential therapy in patients with Stargardt disease. We think it’s an important unmet medical need. And the second, I think you touched on it when you talked about TTRsc04. As a platform company, we really have the opportunity to continuously innovate and bring optionality to how we think about developing our medicines. And I think TTRsc04 is another TTR lowering program that we are moving forward, which we are very excited about. I think the other point that I would like to make, which I think is quite important is just to remind everybody that Vutrisiran actually has orphan disease that we mentioned for TTR amyloidosis, be it polyneuropathy or cardiomyopathy. So, as with many other companies, we are reflecting on the implications that that’s relatively new legislation on how we think about our portfolio. But as a company, we actually think we are very well positioned given our platform and our ability to continue to innovate around our medicines.
Christine Lindenboom
Okay. The next question?
Operator
Our next question comes from the line of Gary Nachman of BMO. Your line is open.
Gary Nachman
Hi. Good morning. If you end up getting the ONPATTRO of APOLLO-B approval, let’s say, end of next year, but then you will be bumping up against the Vutrisiran HELIOS-B data in early ‘24. How much of an impact do you think that might have on your launch of ONPATTRO in CM when physicians will be anticipating this other important data set. I know it’s a bit early thinking about the launches, but given the timing of these, I was curious to get some of your early thoughts on that. Thanks.
Yvonne Greenstreet
Well, so I will just start off by saying that the reason why we progress ONPATTRO in the cardiomyopathy indication just a level of unmet medical need, that’s the patients who continue to progress despite various therapies. And really, we took the opportunity with ONPATTRO to try to bring a near-term solution for these patients, whilst we continue to develop Vutrisiran in our HELIOS-B study. And as you pointed out, we will have those results shortly at the beginning of 2024. So, we think that we are able to meet the needs of patients in the near-term hopefully with the approval of ONPATTRO and CM. And then as we progress HELIOS-B going forward and even more attractive regimen for these patients shortly afterwards. But maybe Tolga, you can comment on how we are thinking about the launch of ONPATTRO with the opportunity hopefully of bringing Vutrisiran to these patients in the medium-term.
Tolga Tanguler
Yes. No, I think you summarized perfectly, Yvonne. All I would add is there is a big unmet need. There are patients who are currently on available treatments that are continuing to progress. And to your point, we want to make an alternative treatment available as quickly as possible so we can actually meet those needs and also continue to build our capabilities for the larger indication. We are obviously very pleased with the capabilities that we have built based on what we are actually able to demonstrate with AMVUTTRA CM [ph] launch. And as we continue to expand the indication, we believe our experience with the CM is going to help us to have even a stronger launch with AMVUTTRA CM, if it’s approved.
Yvonne Greenstreet
Thanks Tolga, that’s great. So again, the sort of TTR franchise approach, which we think will be important for patients and our commercial performance going forward.
Christine Lindenboom
Next question.
Operator
Thank you. Our next question comes from Luca Issi of RBC Capital.
Luca Issi
Hey. Great. Thanks so much for taking my question. Maybe one on the pipeline, if I may. So, maybe on APP, kind of any additional color on why the readout has been pushed out? And maybe bigger picture, can you level set expectations to-date the next year? Wht reduction in CSF APP alpha and beta would you consider it meaningful? And maybe what’s the earliest we could possibly see functional data for that data set? Thanks so much.
Yvonne Greenstreet
Great. Thank you, Luca, for a question on APP. Look, we are clearly excited about the potential for RNAi therapeutics and addressing CNS diseases. This is the first one out of the gate and we are progressing kind of very well, but thoughtfully as Akshay described in his introductory remarks. But actually, maybe you can speak to the data that we are expecting after the ongoing study.
Akshay Vaishnaw
Yes. The crucial data, I think first and foremost is safety. This is our first candidate in central nervous system. So, that’s a keen interest. The study is progressing well. So, we are very comfortable so far. Beyond that, obviously, there is lots of interest in the biomarker outlook. And so we will be looking for APP knockdown and the fragments therapeutic trail from APP changes in those of the CNS APP. And in addition to that, there is going to be important PK because, again, it’s the first time we have injected that have to [indiscernible]. So, those are the key data points in the short-term that we will be looking at and looking forward to reporting in early ‘23.
Yvonne Greenstreet
Absolutely. And as we move forward in APP, we are able to demonstrate the impact on patients with – anyone with Alzheimer’s disease. The quarter opens up the opportunity for a whole host of other devastating CNS supporters. So, a very important program for us, we are progressing well. Thank you for the question.
Christine Lindenboom
Next question please.
Operator
Thank you. Our next question comes from Joseph Stringer of Needham & Company. Your line is open.
Joseph Stringer
Hi. Good morning. Thanks taking our question. A question on AMVUTTRA start forms in the percentage sourced from new prescribers. I think this quarter you have around 17%, that was similar to 20% from your last update. Do you sort of see this continuing and fairly stable in that 15% to 20% range going forward, or how do you see that going forward? Thank you.
Akshay Vaishnaw
Tolga, that’s clearly a question for you. How do you see the percentage of new prescribers going forward?
Tolga Tanguler
Yes. Look, I mean I am glad you have highlighted that. We are really excited about sort of how we are displaying those strong foundational capabilities that we have been able to build from diagnosis all the way to access support. One of those excitements is we see a healthy balance of physicians, both from academic centers and community specialists, start prescribing this medication. And as you pointed out, another important metric is the new prescribers. We see a steady increase of this new specialist around 20% month-after-month being added to the prescriber base. And as a result of that, we also see patients are treated a bit younger, a sign that patients are getting diagnosed and obviously, they are getting the AMVUTTRA treatment. Another important metric that we also see and where we are obviously going to pay a lot of attention to this is our start forms to treatment rates, despite having a temporary J-code, it’s been similar to ONPATTRO. And again, thanks to our good access support, VBAs and our price parity strategy. So, because of those elements, we believe we are going to continue to see a good expansion of new prescribers and net new patients for AMVUTTRA that’s going to drive the TTR franchise to the next level.
Joseph Stringer
Super. Thank you very much.
Yvonne Greenstreet
And I think we have got time for one more question.
Operator
Thank you. Our next question comes from Myles Minter of William Blair. Your line is open.
Myles Minter
Hi. Thanks for squeezing me in. Just on OXLUMO actually, just with the recent FDA label expansion. Are you expecting like a significant amount of warehouse advanced PH1 patients. And I guess, how are you thinking about growing that franchise moving forward, considering it looks somewhat flat over the past quarters? Thanks.
Yvonne Greenstreet
Tolga, do you want…?
Tolga Tanguler
Look, GIVLAARI [ph] is a devastating disease and we are very pleased to be able to actually provide important treatment for these ultra-rare disease patients. LMHC has been a great addition – we do see a good addition to our data suite of data that we have. We see a good group of patients, both from pediatric and as adults level as well as various progressive stage of their diseases. It eliminates is simply another important element that will allow the prescribers to be able to prescribe this medicine to a broad range of patients that suffer from this ultra-rare disease.
End of Q&A
Yvonne Greenstreet
Look, we have had a great quarter. We really are based in our commercial performance and we are seeing strong growth in patients on therapy across all of our commercial portfolio. So, I am certainly very pleased with our performance. So, thank you everyone for joining us on this call. Great progress in the third quarter of 2022, we talked about our strong commercial results, but also we are pleased with how we are advancing our diverse pipeline programs that are in development. A lot of excitement ahead, cashless on deck in the coming months and we of course, look forward to updating you along the way as we continue to deliver on our near and long-term goals. So, thank you everybody and have a great day.
Operator
Thank you. Ladies and gentlemen, this does conclude today’s conference. Thank you all for participating. You may now disconnect. Have a great day.